A phase II study evaluated the efficacy of lenvatinib in combination with the anti-PD-L1 immune checkpoint inhibitor (ICI) pembrolizumab (an anti-PDL1 antibody) in patients with metastatic ATC or poorly differentiated thyroid carcinoma (PDTC) (NCT02973997). This evidence concerns the gene CD274 and poorly differentiated thyroid gland carcinoma.